Phage-Drug Nanoconjugates: A Breakthrough in Combating AMR
Innovative Phage-drug Nanoconjugates to Combat Antimicrobial Resistance
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This technology introduces phage-drug nanoconjugates that effectively target antimicrobial-resistant bacteria and disrupt protective biofilms. By linking active agents to bacteriophages via cleavable linkers, the system ensures targeted delivery and controlled release of therapeutics, enhancing treatment efficacy. Applications include combating hospital-acquired infections, persistent biofilm-related diseases, and multidrug-resistant pathogens like Pseudomonas aeruginosa. The innovation combines phage specificity with drug efficacy, addressing critical gaps in AMR treatment. Protected under PCT/AU2022/051426, this platform offers a versatile therapeutic solution for diverse infection control methods, including inhalable, oral, and wound dressing products.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Public Health & Universal Healthcare
